fashion -WSS

fashion

author：explore 2025-09-28 04:58:57 - browse：2

The corporate offices of Massachusetts General Brigham hospitals in Assembly Square in Somerville. Lane Turner/Globe Staff

The severing of ties between two of Boston’s biggest health care giants has placed one of the nation’s largest health care systems in the position of figuring out how, exactly, to fill a new hole in its oncology services, at a time when cancer care is changing rapidly.

Earlier this month, Dana-Farber Cancer Institute surprised the medical community and even its partner, Brigham and Women’s Hospital, when it announced that it would end their nearly 30-year collaboration. The split will take a few years to play out — Dana-Farber and Brigham and Women’s have a contract into 2028 — but has shaken patients and physicians.

Anne Klibanski, chief executive of Brigham and Women’s parent organization, Mass General Brigham, placed the blame on Dana-Farber executives. The two parties had been in discussions about extending their contract for months when the split was announced. “The decision was made by the Farber. It was announced. Now, we just have to plan forward,” she said. Klibanski shared her views on the split at a meeting with Boston Globe opinion editors on Thursday.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： How to address the problem of discarded donor organs

hotspot

focus

WSS

How to fix the rural physician shortage in the U.S.

As health system earnings go up, health insurance stocks go down

Obesity now affects over 1 billion people worldwide, study finds

AstraZeneca loses challenge to Medicare drug price negotiation

FDA does about

Is it ever OK for doctors to lie to their patients?

Wikipedia

fashion

Wikipedia

Medicare proposal to cover medical devices draws a mixed reaction

AltruBio raises $225 million to develop ulcerative colitis drug

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Has Bernie Sanders reached the limit of his pharma bullying effort?

Jerome Adams on the need for new antivirals for Covid

RSV vaccines may be linked to small increased risk of developing GBS

Psychedelics group wrestles with new pharma identity

AstraZeneca loses challenge to Medicare drug price negotiation

Moonlake's readout produced a cash windfall. Risks remain

GSK’s asthma push continues as drug succeeds in Phase 3 trials

focus

AI for drug discovery: Experts on separating hype from reality

Black vets could get higher VA benefits if race not used in lung test

Flu vaccine offering decent levels of protection this winter, new data show

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Warren pushes Witty on UnitedHealth's control over physicians

How a small hospital in rural Puerto Rico survived Hurricane Maria

leisure time

hotspot

focus

hotspot